Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aravive, Inc. (ARAV)

1.79   0.08 (4.68%) 01-27 15:59
Open: 1.71 Pre. Close: 1.71
High: 1.79 Low: 1.64
Volume: 109,572 Market Cap: 107(M)

Technical analysis

as of: 2023-01-27 4:42:33 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.13     One year: 2.49
Support: Support1: 1.43    Support2: 1.19
Resistance: Resistance1: 1.83    Resistance2: 2.13
Pivot: 1.71
Moving Average: MA(5): 1.74     MA(20): 1.63
MA(100): 1.27     MA(250): 1.32
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 76.5     %D(3): 77.7
RSI: RSI(14): 61.3
52-week: High: 2.4  Low: 0.57
Average Vol(K): 3-Month: 572 (K)  10-Days: 90 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ARAV ] has closed below upper band by 14.0%. Bollinger Bands are 62.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.79 - 1.8 1.8 - 1.81
Low: 1.62 - 1.63 1.63 - 1.64
Close: 1.77 - 1.79 1.79 - 1.8

Company Description

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Headline News

Sun, 29 Jan 2023
Ridgewood Crew Competes in Ironmen Erg Classic | Ridgewood ... -

Fri, 27 Jan 2023
Feb 4 | Tu B'Shevat Seder Celebration | Santa Monica, CA Patch - Patch

Wed, 18 Jan 2023
Kaali Venkat joins the cast of Arav, Ramya Pandian film - cinemaexpress

Tue, 17 Jan 2023
Shivaji gymnasts rule the roost - The Hitavada

Sun, 15 Jan 2023
Akshay Kumar's son Aarav was stopped at Mumbai airport for this ... -

Wed, 04 Jan 2023
Aravive Completes Enrollment in Phase 3 Trial for Ovarian Cancer; Shares Rise -

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 60 (M)
Shares Float 18 (M)
% Held by Insiders 49.2 (%)
% Held by Institutions 25.6 (%)
Shares Short 800 (K)
Shares Short P.Month 530 (K)

Stock Financials

EPS -2.13
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.49
Profit Margin (%) 0
Operating Margin (%) -747.4
Return on Assets (ttm) -67.9
Return on Equity (ttm) -173.5
Qtrly Rev. Growth 105.5
Gross Profit (p.s.) -0.51
Sales Per Share 0.14
EBITDA (p.s.) -1.07
Qtrly Earnings Growth 0
Operating Cash Flow -59 (M)
Levered Free Cash Flow -33 (M)

Stock Valuations

PE Ratio -0.85
PEG Ratio -0.1
Price to Book value 3.65
Price to Sales 12.38
Price to Cash Flow -1.81

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2018-10-15
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.